KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway.

KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway.
复制标题

KLHL38 通过激活 Akt 信号通路参与非小细胞肺癌进展

DOI:
10.1038/s41419-021-03835-0
复制
发表时间:
2021-05-28
影响因子:
9
通讯作者:
Qiu X
Qiu X
中科院分区:
生物学1区
文献类型:
--
作者:
Xu Y;Wang C;Jiang X;Zhang Y;Su H;Jiang J;Ren H;Qiu X

文献摘要

参考文献

相似文献

肺癌是全球癌症相关死亡的主要原因。据报道,KLHL38在滞育期间上调,但在雄激素治疗后,在雄激素依赖性骨骼肌萎缩逆转期间下调。本研究旨在阐明KLHL38在非小细胞肺癌(NSCLC)中的作用。应用免疫组织化学和实时荧光定量聚合酶链式反应技术检测241例非小细胞肺癌患者肿瘤及癌旁正常组织中KLHL38的表达,并分析其与临床病理参数的关系。KLHL38水平与肿瘤大小、淋巴结转移、病理分期呈正相关(P均<0.001)。在非小细胞肺癌细胞系中,KLHL38过表达促进PTEN泛素化,从而激活Akt信号。它还通过上调细胞周期蛋白D1、细胞周期蛋白B、c-myc、RhoA和MMP9的表达,下调p21和E-钙粘蛋白的表达,促进细胞的增殖、迁移和侵袭。裸鼠体内实验进一步证实KLHL38通过激活Akt信号通路促进非小细胞肺癌进展。这些结果表明,KLHL38是一个有价值的NSCLC的候选预后生物标志物和潜在的治疗靶点。
Lung cancer is the leading cause of cancer-related death worldwide. KLHL38 has been reported to be upregulated during diapause but downregulated after androgen treatment during the reversal of androgen-dependent skeletal muscle atrophy. This study aimed to clarify the role of KLHL38 in non-small cell lung cancer (NSCLC). KLHL38 expression was evaluated in tumor and adjacent normal tissues from 241 patients with NSCLC using immunohistochemistry and real-time PCR, and its association with clinicopathological parameters was analyzed. KLHL38 levels positively correlated with tumor size, lymph node metastasis, and pathological tumor-node-metastasis stage (allP< 0.001). In NSCLC cell lines,KLHL38overexpression promoted PTEN ubiquitination, thereby activating Akt signaling. It also promoted cell proliferation, migration, and invasion by upregulating the expression of genes encoding cyclin D1, cyclin B, c-myc, RhoA, and MMP9, while downregulating the expression of p21 and E-cadherin. In vivo experiments in nude mice further confirmed that KLHL38 promotes NSCLC progression through Akt signaling pathway activation. Together, these results indicate that KLHL38 is a valuable candidate prognostic biomarker and potential therapeutic target for NSCLC.
DOI: 10.1186/s12864-015-2210-0
发表时间: 2015-11-23
期刊: BMC genomics
影响因子: 4.4
作者:
Mesak F;Tatarenkov A;Avise JC
通讯作者: Avise JC
DOI: 10.1186/s13046-018-0855-7
发表时间: 2018-08-13
期刊: Journal of experimental & clinical cancer research : CR
影响因子: --
作者:
Jiang J;Xu Y;Ren H;Wudu M;Wang Q;Song X;Su H;Jiang X;Jiang L;Qiu X
通讯作者: Qiu X
DOI: 10.1158/0008-5472.can-08-4055
发表时间: 2009-04-15
期刊: Cancer research
影响因子: 11.2
作者:
Sos ML;Koker M;Weir BA;Heynck S;Rabinovsky R;Zander T;Seeger JM;Weiss J;Fischer F;Frommolt P;Michel K;Peifer M;Mermel C;Girard L;Peyton M;Gazdar AF;Minna JD;Garraway LA;Kashkar H;Pao W;Meyerson M;Thomas RK
通讯作者: Thomas RK
DOI: 10.1186/s13578-020-00499-9
发表时间: 2020-11-27
期刊: Cell & bioscience
影响因子: 7.5
作者:
Jiang X;Xu Y;Ren H;Jiang J;Wudu M;Wang Q;Guan J;Su H;Zhang Y;Zhang B;Guo Y;Hu Y;Jiang L;Liu Z;Wang H;Cheng Y;Sun L;Qiu X
通讯作者: Qiu X
DOI: 10.3892/ijmm.2014.1701
发表时间: 2014-05
影响因子: 5.4
作者:
Liu L;Wang Y;Yu Q
通讯作者: Yu Q